Drug intelligence / Profile preview

KROS-401

Development stage: Preclinical
Lead developer: Kairos Pharma
Modality: Peptides

Overview

KROS-401 is a cyclic peptide inhibitor developed by Kairos Pharma that targets the Interleukin-4 (IL-4) and Interleukin-13 (IL-13) cytokine receptor complex. By inhibiting these pathways, KROS-401 acts as a tumor microenvironment immune modulator, specifically reversing the transition of macrophages from the pro-inflammatory M1 phenotype to the immunosuppressive M2 phenotype. This mechanism is designed to mitigate immune suppression in advanced cancers, such as triple-negative breast cancer and glioma, and has also shown potential in treating fibrosis by reversing the M1 to M2 transition. As of early 2024, the drug is in preclinical development and has been evaluated in animal models.

Other names: KROS-401KROS401KROS 401

Targets

IL4R (Interleukin-4 receptor alpha subunit)IL13RA1 (Interleukin-13 receptor subunit alpha-1)

Beyond the preview

Go deeper on KROS-401.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KROS-401.

Explore the full profile